Actionable Genes, Core Databases, and Locus-Specific Databases

Human Mutation

Volumn 37, Issue 12, 2016, Pages 1299-1307

  Pinard, Amélie ^a   Miltgen, Morgane ^a   Blanchard, Arnaud ^a   Mathieu, Hélène ^a   Desvignes, Jean Pierre ^a   Salgado, David ^a   Fabre, Aurélie ^a,b   Arnaud, Pauline ^c,d,e   Barré, Laura ^a   Krahn, Martin ^a,b   Grandval, Philippe ^a,b   Olschwang, Sylviane ^a,b,f,g   Zaffran, Stéphane ^a   Boileau, Catherine ^c,d,e   Béroud, Christophe ^a,b   Collod Béroud, Gwenaëlle ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b TIMONE HOSPITAL   (France)

^c BICHAT HOSPITAL   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e Site Xavier Bichat and Département Hospitalo Universitaire Fibrosis Inflammation and Remodeling   (France)

^f Department of Neurosurgery   (France)

^g Unité de médecine interne Hôpital européen   (France)

Author keywords

actionable genes; databases; LSDB; NGS; secondary variant

Indexed keywords

ARTICLE; ATHEROSCLEROSIS; CANCER SUSCEPTIBILITY; FILTRATION; GENE ACTIVITY; GENE FREQUENCY; GENE LOCUS; GENE MUTATION; GENETIC DATABASE; GENETIC VARIATION; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PHENOTYPE; PRIORITY JOURNAL; BIOLOGY; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; MOLECULAR GENETICS; MUTATION; NEOPLASM; SOFTWARE;

ATHEROSCLEROSIS; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MOLECULAR SEQUENCE ANNOTATION; MUTATION; NEOPLASMS; SOFTWARE;

EID: 84992463393     PISSN: 10597794     EISSN: 10981004     Source Type: Journal    
DOI: 10.1002/humu.23112     Document Type: Article

References (52)

1. 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S, McVean GA, Abecasis GR. 2015. A global reference for human genetic variation. Nature 526:68–74.
2. ACMG Board of Directors. 2015. ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing. Genet Med 17:68–69.
3. Adzhubei I, Jordan DM, Sunyaev SR. 2013. Predicting functional effect of human missense mutations using PolyPhen-2. Curr Protoc Hum Genet Chapter 7: Unit7.20.
4. Amendola LM, Dorschner MO, Robertson PD, Salama JS, Hart R, Shirts BH, Murray ML, Tokita MJ, Gallego CJ, Kim DS, Bennett JT, Crosslin DR, et al. 2015. Actionable exomic incidental findings in 6503 participants: challenges of variant classification. Genome Res 25:305–315.
5. American College of Medical Genetics and Genomics. 2013. Incidental findings in clinical genomics: a clarification. Genet Med 15:664–666.
6. Andorno R. 2004. The right not to know: an autonomy based approach. J Med Ethics 30:435–439; discussion 439–440.
7. Bean LJH, Hegde MR. 2016. Gene variant databases and sharing: creating a global genomic variant database for personalized medicine. Hum Mutat 37:559–563.
8. Béroud C, Hamroun D, Collod-Beroud G, Boileau C, Soussi T, Claustres M. 2005. UMD (Universal Mutation Database): 2005 update. Hum Mutat 26:184–191.
9. Beroud C, Letovsky SI, et al. 2016. BRCA Share: A Collection of Clinical BRCA Gene Variants. Hum Mutat 37.
10. Biesecker LG. 2013. Incidental variants are critical for genomics. Am J Hum Genet 92:648–651.
11. Burke W, Antommaria AHM, Bennett R, Botkin J, Clayton EW, Henderson GE, Holm IA, Jarvik GP, Khoury MJ, Knoppers BM, Press NA, Ross LF, et al. 2013. Recommendations for returning genomic incidental findings? We need to talk! Genet Med 15:854–859.
12. Choi Y, Sims GE, Murphy S, Miller JR, Chan AP. 2012. Predicting the functional effect of amino acid substitutions and indels. PLoS ONE 7:e46688.
13. Christenhusz GM, Devriendt K, Dierickx K. 2013. Secondary variants–in defense of a more fitting term in the incidental findings debate. Eur J Hum Genet 21:1331–1334.
14. Clayton EW, Haga S, Kuszler P, Bane E, Shutske K, Burke W. 2013. Managing incidental genomic findings: legal obligations of clinicians. Genet Med 15:624–629.
15. Dalgleish R. 2016. LSDBs and how they have evolved. Hum Mutat 37:532–539.
16. Desmet F-O, Hamroun D, Lalande M, Collod-Beroud G, Claustres M, Béroud C. 2009. Human Splicing Finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 37:e67.
17. Dorschner MO, Amendola LM, Turner EH, Robertson PD, Shirts BH, Gallego CJ, Bennett RL, Jones KL, Tokita MJ, Bennett JT, Kim JH, Rosenthal EA, et al. 2013. Actionable, pathogenic incidental findings in 1,000 participants' exomes. Am J Hum Genet 93:631–640.
18. Douglas MP, Ladabaum U, Pletcher MJ, Marshall DA, Phillips KA. 2016. Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review. Genet Med 18:111–116.
19. Fokkema IFAC, Dunnen den JT, Taschner PEM. 2005. LOVD: easy creation of a locus-specific sequence variation database using an “LSDB-in-a-box” approach. Hum Mutat 26:63–68.
20. Fu W, O'Connor TD, Jun G, Kang HM, Abecasis G, Leal SM, Gabriel S, Rieder MJ, Altshuler D, Shendure J, Nickerson DA, Bamshad MJ, et al. 2013. Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. Nature 493:216–220.
21. Gambin T, Jhangiani SN, Below JE, Campbell IM, Wiszniewski W, Muzny DM, Staples J, Morrison AC, Bainbridge MN, Penney S, McGuire AL, Gibbs RA, et al. 2015. Secondary findings and carrier test frequencies in a large multiethnic sample. Genome Med 7:54.
22. Gliwa C, Berkman BE. 2013. Do researchers have an obligation to actively look for genetic incidental findings? Am J Bioeth 13:32–42.
23. González-Pérez A, López-Bigas N. 2011. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. Am J Hum Genet 88:440–449.
24. Green RC, Berg JS, Grody WW, Kalia SS, Korf BR, Martin CL, McGuire AL, Nussbaum RL, O'Daniel JM, Ormond KE, Rehm HL, Watson MS, et al. 2013. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet Med 15:565–574.
25. Hegde M, Bale S, Bayrak-Toydemir P, Gibson J, Bone Jeng LJ, Joseph L, Laser J, Lubin IM, Miller CE, Ross LF, Rothberg PG, Tanner AK, et al. 2015. Reporting incidental findings in genomic scale clinical sequencing—a clinical laboratory perspective: a report of the Association for Molecular Pathology. J Mol Diagn 17:107–117.
26. Johnston JJ, Rubinstein WS, Facio FM, Ng D, Singh LN, Teer JK, Mullikin JC, Biesecker LG. 2012. Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. Am J Hum Genet 91:97–108.
27. Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. 2014. A general framework for estimating the relative pathogenicity of human genetic variants. Nat Genet 46:310–315.
28. Landrum MJ, Lee JM, Benson M, Brown G, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Hoover J, Jang W, Katz K, et al. 2016. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res 44:D862–D868.
29. Lek M, Karczewski K, Minikel E, Samocha K, Banks E. 2015. Analysis of protein-coding genetic variation in 60,706 humans. Nature 536:285–291.
30. Matthijs G, Souche E, Alders M, Corveleyn A, Eck S, Feenstra I, Race V, Sistermans E, Sturm M, Weiss M, Yntema H, Bakker E, et al. 2016. Guidelines for diagnostic next-generation sequencing. Eur J Hum Genet 24:2–5.
31. Olfson E, Cottrell CE, Davidson NO, Gurnett CA, Heusel JW, Stitziel NO, Chen L-S, Hartz S, Nagarajan R, Saccone NL, Bierut LJ. 2015. Identification of medically actionable secondary findings in the 1000 Genomes. PLoS One 10:e0135193.
32. Park JY, Clark P, Londin E, Sponziello M, Kricka LJ, Fortina P. 2015. Clinical exome performance for reporting secondary genetic findings. Clin Chem 61:213–220.
33. Reese MG, Eeckman FH, Kulp D, Haussler D. 1997. Improved splice site detection in Genie. J Comput Biol 4:311–323.
34. Reva B, Antipin Y, Sander C. 2011. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res 39:e118.
35. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL, et al. 2015. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 17:405–423.
36. Salgado D, Desvignes JP, Rai G, Blanchard A, Miltgen M, Pinard A, Lévy N, Collod-Beroud G, Béroud C. 2016. UMD-Predictor: a high-throughput sequencing compliant system for pathogenicity prediction of any human cDNA substitution. Hum Mutat 37:439–446.
37. Salgado D, Bellgard MI, Desvignes JP, Béroud C. 2016. How to identify pathogenic mutations among all those variations: variant annotation and filtration in the genome sequencing era. Hum Mutat.
38. Scheuner MT, Peredo J, Benkendorf J, Bowdish B, Feldman G, Fleisher L, Mulvihill JJ, Watson M, Herman GE, Evans J. 2015. Reporting genomic secondary findings: ACMG members weigh in. Genet Med 17:27–35.
39. Schwarz JM, Cooper DN, Schuelke M, Seelow D. 2014. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods 11:361–362.
40. Sherry ST, Ward MH, Kholodov M, Baker J, Phan L, Smigielski EM, Sirotkin K. 2001. dbSNP: the NCBI database of genetic variation. Nucleic Acids Res 29:308–311.
41. Sim N-L, Kumar P, Hu J, Henikoff S, Schneider G, Ng PC. 2012. SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res 40:W452–W457.
42. Smith PJ, Zhang C, Wang J, Chew SL, Zhang MQ, Krainer AR. 2006. An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Gen 15:2490–2508.
43. Soussi T, Ishioka C, Claustres M, Béroud C. 2006. Locus-specific mutation databases: pitfalls and good practice based on the p53 experience. Nat Rev Cancer 6:83–90.
44. Stenson PD, Mort M, Ball EV, Shaw K, Phillips A, Cooper DN. 2014. The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Gen 133:1–9.
45. Stheneur C, Collod-Béroud G, Faivre L, Buyck JF, Gouya L, Le Parc J-M, Moura B, Muti C, Grandchamp B, Sultan G, Claustres M, Aegerter P, et al. 2009. Identification of the minimal combination of clinical features in probands for efficient mutation detection in the FBN1 gene. Eur J Hum Genet 17:1121–1128.
46. Tennessen JA, Bigham AW, O'Connor TD, Fu W, Kenny EE, Gravel S, McGee S, Do R, Liu X, Jun G, Kang HM, Jordan D, et al. 2012. Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science 337:64–69.
47. van El CG, Cornel MC, Borry P, Hastings RJ, Fellmann F, Hodgson SV, Howard HC, Cambon-Thomsen A, Knoppers BM, Meijers-Heijboer H, Scheffer H, Tranebjaerg L, et al. 2013. Whole-genome sequencing in health care. Recommendations of the European Society of Human Genetics. Eur J Hum Genet 21(Suppl 1):S1–S5.
48. Vihinen M, Hancock JM, Maglott DR, Landrum MJ, Schaafsma GCP, Taschner P. 2016. Human Variome Project quality assessment criteria for variation databases. Hum Mutat 37:549–558.
49. Wang K, Li M, Hakonarson H. 2010. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res 38:e164.
50. Xue Y, Chen Y, Ayub Q, Huang N, Ball EV, Mort M, Phillips AD, Shaw K, Stenson PD, Cooper DN, Tyler-Smith C, 1000 Genomes Project Consortium. 2012. Deleterious- and disease-allele prevalence in healthy individuals: insights from current predictions, mutation databases, and population-scale resequencing. Am J Hum Genet 91:1022–1032.
51. Yavarna T, Al-Dewik N, Al-Mureikhi M, Ali R, Al-Mesaifri F, Mahmoud L, Shahbeck N, Lakhani S, AlMulla M, Nawaz Z, Vitazka P, Alkuraya FS, et al. 2015. High diagnostic yield of clinical exome sequencing in Middle Eastern patients with Mendelian disorders. Hum Gen 134:967–980.
52. Yeo G, Burge CB. 2004. Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol 11:377–394.